WaveMan
WaveMan · Company
ANTX · An2 Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ANTX AN2 Therapeutics (ANTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001880438
Quote by TradingView
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
43
13F, latest reported quarter

What the filings say about ANTX

Insiders, 180 days
-$332.6K net sold
1 buyer · 3 sellers · 73% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$6.1M
1 notice

AN2 Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, AN2 Therapeutics, Inc. insiders sold a net $332.6K of stock across 138 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Readnour Robin Shane
Director
SELL
2026-09-11 SECtraded 2026-09-09
523
$3.2K
-29.3%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (13 buys, 10 sales), the last on Sep 8, 2026.
  • -11.5% median (-14.0% mean) 90-day return after 8 previous buys.
  • The trade is 0.1% of the 557,467 shares held after it.
  • 1 other insider sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Readnour Robin Shane sold about $3.2K of ANTX under a 10b5-1 plan on Sep 9, 2026; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.
Readnour Robin Shane
Director
SELL
2026-09-11 SECtraded 2026-09-09
585
$3.5K
-29.3%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (13 buys, 10 sales), the last on Sep 8, 2026.
  • -11.5% median (-14.0% mean) 90-day return after 8 previous buys.
  • The trade is 0.1% of the 624,765 shares held after it.
  • 1 other insider sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Readnour Robin Shane sold about $3.5K of ANTX under a 10b5-1 plan on Sep 9, 2026; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.
Readnour Robin Shane
Director
SELL
2026-09-08 SEC
4,725
$28.4K
-32.6%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (13 buys, 8 sales), the last on Sep 3, 2026.
  • -11.5% median (-14.0% mean) 90-day return after 8 previous buys.
  • The trade is 0.8% of the 557,990 shares held after it.
  • 1 other insider sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Readnour Robin Shane sold about $28.4K of ANTX under a 10b5-1 plan on Sep 8, 2026; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.
Readnour Robin Shane
Director
SELL
2026-09-08 SEC
5,294
$31.9K
-32.6%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (13 buys, 8 sales), the last on Sep 3, 2026.
  • -11.5% median (-14.0% mean) 90-day return after 8 previous buys.
  • The trade is 0.8% of the 625,350 shares held after it.
  • 1 other insider sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Readnour Robin Shane sold about $31.9K of ANTX under a 10b5-1 plan on Sep 8, 2026; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.
Readnour Robin Shane
Director
SELL
2026-09-08 SECtraded 2026-09-03
2,877
$17.5K
-32.6%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (13 buys, 6 sales), the last on Aug 17, 2026.
  • -11.5% median (-14.0% mean) 90-day return after 8 previous buys.
  • The trade is 0.5% of the 562,715 shares held after it.
  • 1 other insider sold within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Readnour Robin Shane sold about $17.5K of ANTX under a 10b5-1 plan on Sep 3, 2026; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.
138 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 133 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$332.6K over 180 days
-$306.6K over 90 days
below 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
43 funds bought in last quarter
below 56% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.0% of the float short (float per yahoo 2026-10-27) · 7.4 days to cover · settled 2026-10-15
more than 63% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ANTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+229.9%12M
-12%+138%+287%+437%2025-102025-122026-022026-042026-062026-082026-10 2026-08-17 · Readnour Robin Shane sold $112.4K2026-08-17 · Readnour Robin Shane sold $100.3K2026-09-08 · Readnour Robin Shane sold $31.9K2026-09-08 · Readnour Robin Shane sold $28.4K2026-07-08 · Eizen Joshua M sold $24.8K2026-09-03 · Readnour Robin Shane sold $19.6K2026-01-05 · Eizen Joshua M sold $17.9K2026-09-03 · Readnour Robin Shane sold $17.5K2026-09-01 · FitzPatrick Margaret M bought $11.6K2026-01-06 · Eizen Joshua M sold $7.0K2026-01-06 · Chanda Sanjay sold $6.0K2026-01-06 · Day Lucy sold $5.6K2026-01-05 · Prior Stephen David sold $3.6K2026-09-09 · Readnour Robin Shane sold $3.5K2026-01-05 · Day Lucy sold $3.3K2026-01-05 · Chanda Sanjay sold $3.3K2025-11-04 · Eizen Joshua M sold $3.2K2026-09-09 · Readnour Robin Shane sold $3.2K2026-01-06 · Prior Stephen David sold $2.9K2026-09-01 · Williams Sarah Joanne sold $1.5K2026-05-29 · Williams Sarah Joanne sold $1.2K2025-11-04 · Prior Stephen David sold $8722026-03-03 · Williams Sarah Joanne sold $3472026-08-17 · Readnour Robin Shane filed to sell $6.1M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ANTX: institutional holders (13F)

13F holdings, latest reported quarter
Vivo Capital, LLC
3,153,640 sh
$15.3M
Commodore Capital LP
2,933,680 sh
$14.2M
MILLENNIUM MANAGEMENT LLC
2,318,692 sh
$11.2M
BlackRock, Inc.
1,665,494 sh
$8.1M
Spruce Street Capital LP
1,661,073 sh
$8.0M

Congress trades in ANTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ANTX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Readnour Robin Shane
Filed 2026-08-17
$6.1M

ANTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$285.6K position · as of 2026-06-30
0.2%
iShares Micro-Cap ETF
$430.0K position · as of 2026-06-30
0.0%
U.S. Small Cap Equity Fund
$159.0K position · as of 2026-07-31
0.0%
1290 VT Micro Cap Portfolio
$28.9K position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$159.3K position · as of 2026-06-30
0.0%
iShares Russell 2000 Value ETF
$946.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
0 active
1
Phase 2
1 active
1
Not applicable
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included. Not annual revenue (USASpending.gov).
Department Of Health And Human Services
DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESI · 2022-09-20
$9.2M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $332.6K sold by insiders over 180 days, 43 funds added last quarter, $6.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ANTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-50.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-46.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-53.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$38.1M-$56.8M-$69.6M-$42.3M
Net income-$35.2M-$51.3M-$64.7M-$41.0M
EPS (diluted)-1.16-1.72-2.74-2.79
Operating cash flow-$29.8M-$49.3M-$53.3M-$33.5M
Cash$19.9M$21.4M$15.6M$27.2M
SEC XBRL, fiscal years, as known on 2026-10-28

ANTX Stock Sonar score 4/7 axes

Find similar shapesCompare

ANTX ranks highest on insider conviction (57th percentile) and profitability (49th), and lowest on risk and compliance (30th), among Pharma & Biotech peers.

Profitability
49
Inputs
  • Return on equity-50.1% · 53 pct, sector of 545
  • Return on assets-46.0% · 47 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-53.0% · 47 pct, sector of 576
Insider conviction
57
Inputs
  • Net Form 4 buying (codes P and S), 180d-$16K · 58 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
44
Inputs
  • Funds adding, latest quarter43 · 44 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
30
Inputs
  • Short interest, % of float+13.0% · 30 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ANTX filings, in plain words

Are AN2 Therapeutics insiders buying or selling ANTX?

In the 180 days to 2026-10-28, AN2 Therapeutics insiders were net sellers, a net $332.6K: $11.6K of purchases and $344.2K of sales reported on Form 4, by 1 buyer and 3 sellers.

Are there planned insider sales of ANTX?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $6.1M of stock; the latest, by Readnour Robin Shane, was filed 2026-08-17.

Read the full summary

In the 180 days to 2026-10-28, AN2 Therapeutics insiders were net sellers of ANTX, a net $332.6K across purchases and sales reported on Form 4 by 1 buyer and 3 sellers. Sales outweighed purchases more than tenfold by value. 73% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $6.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies